- Home
- FNLC vs LUNG Comparison
FNLC vs LUNG Comparison
Compare FNLC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- LUNG
- Stock Information
- Founded
- FNLC 1864
- LUNG 1995
- Country
- FNLC United States
- LUNG United States
- Employees
- FNLC N/A
- LUNG N/A
- Industry
- FNLC Major Banks
- LUNG Industrial Specialties
- Sector
- FNLC Finance
- LUNG Health Care
- Exchange
- FNLC Nasdaq
- LUNG Nasdaq
- Market Cap
- FNLC 303.4M
- LUNG 65.6M
- IPO Year
- FNLC 1999
- LUNG 2020
- Fundamental
- Price
- FNLC $26.79
- LUNG $1.55
- Analyst Decision
- FNLC
- LUNG Buy
- Analyst Count
- FNLC 0
- LUNG 7
- Target Price
- FNLC N/A
- LUNG $7.66
- AVG Volume (30 Days)
- FNLC 15.7K
- LUNG 480.4K
- Earning Date
- FNLC 10-22-2025
- LUNG 10-29-2025
- Dividend Yield
- FNLC 5.52%
- LUNG N/A
- EPS Growth
- FNLC 13.09
- LUNG N/A
- EPS
- FNLC 2.68
- LUNG N/A
- Revenue
- FNLC $85,448,000.00
- LUNG $90,549,000.00
- Revenue This Year
- FNLC N/A
- LUNG $10.30
- Revenue Next Year
- FNLC N/A
- LUNG $14.72
- P/E Ratio
- FNLC $9.86
- LUNG N/A
- Revenue Growth
- FNLC 10.86
- LUNG 18.24
- 52 Week Low
- FNLC $22.11
- LUNG $1.47
- 52 Week High
- FNLC $31.05
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- FNLC 51.58
- LUNG 37.40
- Support Level
- FNLC $26.32
- LUNG $1.60
- Resistance Level
- FNLC $27.32
- LUNG $1.76
- Average True Range (ATR)
- FNLC 0.50
- LUNG 0.13
- MACD
- FNLC -0.10
- LUNG 0.02
- Stochastic Oscillator
- FNLC 36.72
- LUNG 2.86
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.